Effect of abiraterone acetate (AA) and enzalutamide (EZ) administration on chemotherapy-naïve metastatic castration-resistant prostate cancer (CN-mCRPC) patient’s symptom burden.

Sepehr Salem,Maria Komisarenko,N. Timilshina,Frank Jiao,Ruby Grewal,Shabbir M.H. Alibhai,Antonio Finelli

Effect of abiraterone acetate (AA) and enzalutamide (EZ) administration on chemotherapy-naïve metastatic castration-resistant prostate cancer (CN-mCRPC) patient’s symptom burden.

2016

Sepehr Salem
Maria Komisarenko
N. Timilshina
Frank Jiao
Ruby Grewal
Shabbir M.H. Alibhai
Antonio Finelli

e16540Background: Reliable evaluation of the disease burden throughout advanced PC is crucial to the assessment of treatment effectiveness and patient improvement. This study sought to further expl...

Keywords:

Abiraterone acetate
Prostate cancer
Physical therapy
Castration
Cancer research
Enzalutamide
Medicine
Chemotherapy
symptom burden
Oncology
castration resistant
Internal medicine
Disease burden
Pathology
chemotherapy naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations